NA
STOK icon

NewEdge Advisors’s Stoke Therapeutics STOK Stock Holding History

NewEdge Advisors’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,403
Closed -$330K – 4377
2025
Q4 		$330K Buy
+10,403
New +$313K ﹤0.01% 2251
2023
Q1 		– Sell
-75
Closed -$692 – 4076
2022
Q4 		$692 Buy
+75
New +$780 ﹤0.01% 3120

Other funds holding STOK

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

NewEdge Advisors's STOK Position: Q1 2026 in Review

NewEdge Advisors sold out of Stoke Therapeutics (STOK) in Q1 2026, closing a stake of 10,403 shares — an estimated $330K sold.

NewEdge Advisors first reported a position in STOK in Q4 2022 and held it in 2 quarters. The position peaked at $330K in Q4 2025. 198 funds tracked by Wall St. Rank hold STOK as of Q1 2026.

  • NewEdge Advisors reported no remaining Stoke Therapeutics position as of Q1 2026 after selling out during the quarter.
  • NewEdge Advisors sold 10,403 Stoke Therapeutics shares in Q1 2026, an estimated $330K.
  • NewEdge Advisors first reported a position in Stoke Therapeutics in Q4 2022 and held it in 2 quarters.
  • NewEdge Advisors's Stoke Therapeutics position peaked at $330K in Q4 2025.
  • 198 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q1 2026.

Based on NewEdge Advisors's 13F filing for Q1 2026, filed 18 May 2026.